Technology

The UltiMAb technology, licensed from Medarex, uses a strain of transgenic mice, the HuMab-Mouse. The mouse is designed to produce fully-human antibodies which tend to have high affinity for the target and low immunogenicity. Once an antigen target is selected, the UltiMAb system facilitates production of a variety of fully-human antibodies against various epitopes on the target antigen. Over 30 antibodies derived from the UltiMAb technology are in development, with several already marketed, including ofatumumab.

Back to top

 

The DuoBody technology platform offers a natural, unique and easy way to create bispecific antibodies with possible applications in different indications, including oncology, autoimmune disease, inflammation and infectious disease. Bispecific antibodies are the next step towards the development of effective treatments in the already successful field of antibody therapeutics. Genmab is seeking strategic partners interested in licensing the DuoBody platform or participating in the development of DuoBody platform-based therapeutics.

DuoBody Highlights

  • Bispecific antibodies produced from the DuoBody platform can bind to two different epitopes either on the same or on different targets (also known as dual-targeting). By dual targeting, bispecific antibodies may increase specificity and engage multiple effector pathways. Dual targeting may also trigger specific recruitment of effector cells for target cell killing.
  • Antibody sequences derived from any platform can be applied and combined for the generation of new bispecific antibodies, retaining the original antigen binding sites.
  • The DuoBody generation process does not require reformatting, and is suitable for high throughput screening.
  • Manufacturing of DuoBody is based on standard unit operations from a typical IgG1 monoclonal antibody platform process.

 To read more about the DuoBody platform, visit DuoBody.com.

Back to top

The UniBody technology platform creates a stable, smaller antibody format from an inert IgG4 antibody. UniBody has potential application in indications where binding to a target is sufficient for therapeutic efficacy. As Genmab is primarily focused on cancer therapeutics, we seek strategic partners interested in licensing the UniBody platform. 

UniBody Highlights

  • A UniBody molecule is made by deleting the hinge region of a human IgG4 molecule and is about half the size of a normal antibody. Its smaller size may have advantages over conventional antibodies, as it may allow better tissue penetration.
  • The UniBody format is applicable to any existing antibody coding sequence.
  • UniBody molecules have only one arm and bind to only one antigen molecule.
  • The use of human IgG4 antibodies as a basis for the UniBody format prevents activation of the immune system.
  • UniBody molecules possess an Fc domain of IgG which protects the molecule from rapid degradation.

 

Back to top

HexaBody is a novel, proprietary technology for the creation of differentiated antibody therapeutics which enhances the natural target cell killing abilities of antibodies with particular application in cancer and infectious disease, among others. Genmab is seeking strategic partners interested in licensing the HexaBody platform or participating in the development of HexaBody platform-based therapeutics.

Features, Benefits and Potential of HexaBody 

  • Antibodies have a natural ability to eliminate pathogens and tumor cells by various cytotoxic mechanisms. The HexaBody platform potentiates this killing ability of antibodies while retaining regular structure and specificity. 
  • The HexaBody technology requires minimal amino acid modifications, allows all available antibody sequences to be exploited and is easily applied to newly generated as well as existing antibodies.
  • The HexaBody technology can be variously used to create novel differentiated antibody therapeutics, to improve the efficacy of existing antibody products, and to potentially repurpose drug candidates that have been unsuccessful due to lack of potency. 
  • The technology has the potential to enhance antibody therapeutics in major therapeutic areas with broad market potential including cancer and infectious diseases.

 

Back to top